Rigel Tumbles on Phase III RA Failure; Lilly Drug Misses, Too
By Catherine Shaffer
Thursday, December 13, 2012
AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira, sending shares of partner Rigel Pharmaceuticals Inc. plunging by almost 35 percent.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.